Symbols

KDNY(Delisted)

Chinook Therapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KDNY

Chinook Therapeutics, Inc.

A clinical-stage biopharmaceutical company that developing medicines for chronic kidney diseases

Industry

Established Date

Listing Date

04/15/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

214

Fiscal Year Ends

12-31

Website

www.chinooktx.com

Security Type

Common stock

Office address

400 Fairview Avenue North, Suite 900, Seattle, WA, 98109

Business

Introduction

Chinook Therapeutics, Inc., is a clinical-stage biotechnology company that develops precision medicines for kidney disease. The company's product candidates are investigating rare, serious chronic kidney disease opportunities with a clear clinical pathway. The Company's main project is Atlasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases.

Company Financials

EPS

KDNY has released its 2023 Q1 earnings. EPS was reported at -0.85, versus the expected -0.79, missing expectations. The chart below visualizes how KDNY has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

KDNY has released its 2023 Q2 earnings report, with revenue of 1.01M, reflecting a YoY change of 141.15%, and net profit of -66.94M, showing a YoY change of -77.82%. The Sankey diagram below clearly presents KDNY's revenue sources and cost distribution.